Aridis Pharmaceuticals  © 2009-2014 Le3 Web Designs

Site Map   |   Privacy Policy   |   Financial Conflict of Interest Policy


Aridis focuses on anti-infective alternatives to conventional antibiotics.


November 19th, 2014.  Aridis Pharmaceuticals announced today that the company’s product AR-301 was selected as a “Top Project to Watch” in the Infectious Disease category at the upcoming 2014 Therapeutic Area Partnerships conference held in Boston, MA, November 19-21. (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

September 16th, 2014.  Aridis Pharmaceuticals Raises $6.75 Million in Oversubscribed Private Placements (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

News


>> More News


In hospitals, 190 million doses of antibiotics are administered each day.  133 million courses of antibiotics are prescribed by doctors each year”

American College of Physicians

www.acponline.org [02 February 2013]

Our anti-infective drug candidates offer

substantial improvement over conventional antibiotics in: